CURRICULUM VITAE MORAN 2-11-2014 · Clinical Nutrition (2011-12) Clinical Orthopaedics & Related...

Updated 2/11/2014

1

CURRICULUM VITAE Antoinette Moran, M.D.

University of Minnesota

Division of Pediatric Endocrinology East Bldg Rm MB671 2450 Riverside Avenue (UPS/FedEx---2414 South 7th St.)

Minneapolis, MN 55455 Phone 612-624-5409; FAX 612-626-5262; email [email protected]

Education and Training Sept 1976-June 1980 University of Minnesota, Duluth, Bachelor of Science (Biology) July 1980-June 1984 University of Minnesota, Minneapolis, Doctor of Medicine July 1984-June 1987 Department of Pediatrics, University of Minnesota, Pediatric Residency July 1987-June 1990 Department of Pediatrics, Division of Endocrinology, University of

Minnesota, Pediatric Endocrinology Fellowship Academic Positions July 1990-June 1991 Instructor, Department of Pediatrics, University of Minnesota July 1991-June 1999 Assistant Professor, Dept of Pediatrics, University of Minnesota July 1999-June 2004 Associate Professor with Tenure, Pediatrics, University of Minnesota July 2004- present Professor, Pediatrics, University of Minnesota Administrative Appointments July 1996-2009 Director, Pediatric Diabetes Program, University of Minnesota April 2001-2009 Director, Pediatric Endocrinology Fellowship Program July 2009-present Research Director, Pediatric Endocrinology Fellowship Program July 2002-present Division Chief, Pediatric Endocrinology and Diabetes May 2002-present Member, Graduate Faculty in Clinical Research July 2003-2009 Director, Metabolic Core, Islet Transplantation Program Sept 2007-present Faculty, Pediatrics Global Health Program Awards and Honors 1987-89 Juvenile Diabetes Foundation Fellowship Award 1996 University Children's Foundation Research Scholar Award 1996 Alexander Charles Jundt Research Award 1996-2013 Elected by peers for inclusion in Best Doctors in America® 2007-10, 2012-3 Elected by peers for inclusion in Mpls/St.Paul Magazine Top Doctors 2007 First annual recipient, Cystic Fibrosis Foundation’s Richard C. Talamo

Distinguished Clinical Achievement Award, for “research contributions that have had significant influence on the course of the disease"

2008 Inducted member, Academy of Science and Engineering, University of Minnesota, Duluth

2013 Allan Drash Clinical Fellowship for ISPAD Center of Excellence Certification and Licensure License: Minnesota (current); Uganda (2007, 2008, 2013) Certification: American Board of Pediatrics 1989, 1999

Updated 2/11/2014

2

Pediatric Endocrinology Subspecialty Boards 1991, 1999, 2005 Professional Societies 1991-present American Diabetes Association 1992-2000 The Endocrine Society 1992-present (Lawson Wilkins) Pediatric Endocrine Society 1994-2004 Society for Pediatric Research (elected) 2004-2012 American Pediatric Society (elected) 2007-present International Society for Pediatric and Adolescent Diabetes

National and International Committees / Research Study Sections /Service

National Institutes of Health - NIH Special Emphasis Review Panel ZRG1 SBIB-5 (82) R, member 2013 - NIH Special Emphasis Review Panel ZRG1 SBIB-W (59) R, member 2012 - NIDDK Special Emphasis Review Panel ZDK1 GRB-1 (02), member 2012 - NIDDK Special Emphasis Review Panel ZDK1 GRB-1, member 2011 - NIDDK Workshop on CFRD, Chair, 2011 - NIDDK Internal Grant Review, 2011 - NIDDK Special Emphasis Panel ZRG1 PSE-J 03, member, 2010 - NIDDK Special Emphasis Panel ZDK1 GRB-G, member, 2009 - NIDDK Challenge Grant reviewer, 2009 - NIDDK External Advisory Committee, TODAY study, member, 2009 - NIDDK Strategic Plan for Diabetes, member, Special Populations committee, 2009 - NIH Study Section KNOD: regular member 2007-2011 - NIH Study Section KNOD: ad hoc reviewer 2005-7 - DSMB member, Diabetes Research in Children Network (DirecNet), 2007-2013 - Clinical Islet Transplantation Consortium Metabolic Committee, 2007-2009 - NIH Special Emphasis Review Panel, CLTR Clinical Trials Review Committee 2007 - TrialNet Study (2003-present)

o Protocol Chair, anti-IL1β (Canakinamab) (2009-present) o Clinical Monitoring Group (2004-2009; Chair 2007-2009) o Ethics Committee (member 2005-present) o Center Director’s Committee (member 2004-present) o Safety Monitoring Committee (member 2004-6, 2010-present) o Ancillary Studies Committee (member 2010-present)

- NIH Special Emphasis Review Panel ZDK1 GRB-C(M2) member, 2005 - NIDDK Experienced Reviewer Reserve 2004-2006 - NIH Special Emphasis Review Panel ZDK1 GRD-C(O2) member, 2004 - NIH Study Section ZRG1 FO6 Endocrinology, Metabolism, Nutrition and

Reproductive Sciences NRSA Review member, 2003-4 - NIH Study Section ZRG1 SSS3-T10B Innovation Research Metab/Diabetes 2003

Cystic Fibrosis Foundation

- Faculty, CFRD Learning and Leadership Collaborative, 2010-11 - Ad Hoc grant reviewer, TDN, 2010

PROFESSIONAL SERVICE

Updated 2/11/2014

3

- Member, Infant Nutrition Research Advisory Committee, 2010 - Chair, CFF/ADA/LWPES Consensus Conference on CFRD, 2009 - Member, CFF Therapeutics Data Safety Monitoring Board, 2009-present - Member, CFF Clinical Research Committee,1996-present - Consultant, CFF Learning and Leadership Collaboration I, 2003-4; Learning and

Leadership Collaboration II, 2004-5 - Member, CFF Consensus Conference on Nutrition. 2001 - Chair, CFF Consensus Conference on Cystic Fibrosis Related Diabetes. 1998 - Member, CFF Consensus Conference on Cystic Fibrosis Related Diabetes. 1990 - Leadership at annual North American Cystic Fibrosis Conference national meeting:

− Workshop chair, "Endocrine and Bone Abnormalities", Baltimore, MA 10/05 − Workshop chair, "Endocrine Complications of CF", Anaheim, CA 10/03 − Short course director, " Management of CFRD", Baltimore, MA 11/00 − Workshop chair, "Endocrine Abnormalities in CF", Nashville TN 10/97 − Short course director, " Management of CFRD”, Seattle, WA 10/99 − Workshop chair, "GI and Metabolic Abnormalities in CF", Dallas, TX 10/95

American Diabetes Association - Youth Strategies Committee, 2013-2014 - Diabetes Care Editorial Board Member, 2012-15 - Professional Practice Oversight Committee, 2008-2010 - Scientific Sessions Youth Subcommittee 2007-10 - ADA Diabetes EXPO-“Ask the Expert” volunteer, 2008-present - Workshop chair, annual meeting, "Diabetes in Cystic Fibrosis", San Diego, CA 6/99

(Lawson Wilkins) Pediatric Endocrine Society

- Member, International Relations Council, 2011-present - Faculty, “A Current Review of Pediatric Endocrinology”, San Diego, CA 6/2005 - Faculty, “LWPES Fellows Summer School Course”, Greenwich, CT, 12/2004 - Workshop chair, annual meeting, "Pediatric Diabetes", Baltimore, MD, 5/02 - Member, Nominating Committee, LWPES, 2001-3; Chair, 2003-4

Endocrine Society - Oral session chair, annual meeting, "Pediatric Endocrinology", Mpls, MN, 6/97

European Cystic Fibrosis Congress

- Symposium session chair, annual meeting, “Endocrine Problems in Cystic Fibrosis”, Belfast, Northern Ireland, 6/03

- Symposium session chair, annual meeting, "Endocrine Issues in Cystic Fibrosis ", Berlin, Germany, 6/98

International Consortium on Aging in CF

- Endocrinology consultant, Belfast, N. Ireland 6/03; Orange City, CA 10/03; St. Louis, MO 10/04; Heronissos, Crete, Greece 6/05; Baltimore, MA 10/05; Denver,CO 11/06

International Diabetes Federation

- Life For A Child, Medical and Scientific Advisory Board member, 2012-2014

Updated 2/11/2014

4

- Medical chaperone for international youth delegates with diabetes, United Nations Diabetes Day, New York 11/07

International Society for Pediatric and Adolescent Diabetes (ISPAD)

- ISPAD prize 2013: Allan Drash Clinical Fellowship for ISPAD Center of Excellence - Poster Chair, annual international meeting 10/2013, Gothenberg, Sweden - ISPAD representative, organizer and faculty, Team Management of Pediatric

Diabetes in Uganda, Kampala , Uganda 10/2013 - ISPAD representative, 1st East African Diabetes Conference, Arusha,Tanzania,7/2012 - Faculty, ISPAD/ESPE Pediatric Diabetes Team course, Nairobi, Kenya 11/2010 - Poster Chair, annual international meeting 10/2010, Buenos Aires, Argentina - ISPAD representative, IDF Insulin Task Force 2009-present - Member, CFRD consensus conference guidelines committee, 2009, 2014 - Faculty, post-graduate course “African Initiative”, 8/2008, Durban, South Africa - Poster Chair, annual international meeting 8/2008, Durban, South Africa

Ad Hoc National and International Grant Review

- Agency for Healthcare Research and Quality, 2010 - American Institute of Biological Sciences (U.S. Air Force Surgeon General) 2009 - The Australian Cystic Fibrosis Trust 2008 - Boston Area Diabetes Endocrinology Research Center, Massachusetts General Hosp. - The Canadian Cystic Fibrosis Foundation 2005, 2008, 2010, 2011 - The Canadian Institutes of Health Research 2009 - The Dutch Cystic Fibrosis Foundation 2011 - The Italian Cystic Fibrosis Research Foundation 2002, 2005, 2009, 2010, 2013 - Pediatric Endocrine Society 2011, 2013 - UK National Institute for Health Research (NIHR) 2011 - Yale University Research Program (2013)

University of Minnesota Committees

Present Medical School and University Committees - Member, UMN Clinical Research Scientific Assessment Panel 2014-present Member, Graduate School Masters in Clinical Research Admissions 2005-present - Member, Dean’s Research Council 2003-present

Present Department Committees - Member, Pediatric Gastroenterology Search Committee, 2013 - Chair, Clinical Track Committee, 2007-present

Past Medical School and University Committees - Member, AHC Clinical Research Optimization Committee, 2011 - Member, Decade of Discovery grant review committee, 2011 - Medical Advisory Board, UM Amplatz Children’s Hospital Advancement Board 2009

- Member, Scientific Advisory Board, Schultz Diabetes Institute 2009 - Member, Children’s Health Campaign Committee 2009 - Member, K12 Medical Advisory Committee, 2008-2009 - Member, AHC Education, Training and Career Development Committee 2008 - Member, Medical School-UMP Internal Alignment Task Force 2008

Updated 2/11/2014

5

- Member Advisory Committee for Career Development 2007 - Chair, GMEC Internal Review Committee, Medicine Endocrinology Fellowship 2007 - Member, Staff and Affiliation Committee, hospital merger negotiations 2006 - Member, Pediatric Pulmonary Faculty Search Committee 2004-5 - Member, Wallin Center for Diabetes and Obesity Planning Group 2004 - Chair, GMEC Internal Review Committee for Family Practice Residency Program 2004 - Chair, GMEC Internal Review Committee, Medicine Endocrinology Fellowship 2003 - Member, Dept. of Pediatrics Clinical Scholar Mentoring Committee 2003 - Member, Pediatric Department Head Search Committee 2002-2003 - Member, UMP Diabetes Mellitus Care Advisory Committee 2000 - Member, Diabetes Education Program Advisory Committee 1996-2006 - Member, Fairview University Diabetes Steering Committee 1997-8 - Member, Ambulatory Education Committee 1996-7 - Member, Medicine/Pediatrics Clinical Research Committee 1996 - Member, UMHC Program Development Committee 1994-5 - Member, GCRC Scientific Advisory Committee 1994-99

Past Department Committees

- Chair, Pulmonary Division Search Committee 2010-14 - Member, Department Strategic Planning, Community Engagement, 2013 - Member, Pediatric Domain Administrative lead, search committee 2012 - Member, Pediatric Rheumatology faculty search committee, 2009 - Member, Advisory Committee to the Chair 2008-2010 - Member, Medical Advisory Committee, University Pediatrics Foundation 2002-2009 - Member, Pediatric Rheumatology Faculty Search Committee 2008 - Chair, Pulmonary Chief/CF Center Director Search Committee 2007-8 - Member, Academic Planning Committee, 2006-2007 - Member, Pediatric Nephrology Search Committee, 2006 - Chair, Promotions Committee 2005-2006 - Chair, Adolescent Medicine Division Head Search Committee 2005-6 - Chair, Director of Medical Education Search Committee 2005 - Chair, Pediatric Gastroenterology Division Head Search Committee 2005 - Member, Pediatric Department Research Committee 2001-2004 - Member, Clinical and Translational Research Committee 2003 - Member, Task Force on the Integration of the Dept. of Peds. / Children Hospital 2001 - Member, Faculty Development Committee 1994 - Member, Residency Selection Committee 1989-2004

International Medical Volunteer Service

- Organizer and faculty, “Team management of pediatric diabetes in Uganda” (CDiC launch), Kampala, Uganda, 2013

- Faculty, 1st East African Diabetic Youth Leadership Program and Pediatric Post-Graduate Course; Arusha, Tanzania 7/2012

- Faculty, ISPAD/ESPE Pediatric Diabetes Team course, Nairobi, Kenya 11/2010 - Visiting physician, Coimbatore, India 3/2009 - Faculty, ISPAD post-graduate course “African Initiative”, 8/2008, Durban, South Africa

Updated 2/11/2014

6

- Visiting physician, Mulago Hospital, Kampala, Uganda, (as a representative of the University of Minnesota Global Health Program) 6/2007, 7/2008, 9/2013. Working with a Ugandan team to develop a Pediatric Diabetes Program

Community Volunteer Service Committees

- Member, Minnesota Diabetes Steering Committee, MN Dept. of Health 2001-2006 - Member, Minnesota Diabetes Steering Committee Surveillance and Data Review

Subcommittee 2002-2006 Diabetes Camp

- Volunteer staff physician, American Diabetes Association Camp Needlepoint, one week each summer, 1996-2005

Rural Physicians Associate Program -annual visiting physician, 1991-2001 Ad Hoc Manuscript Review

Acta Diabetologia (2010) Acta Paediatrica (1992-3, 2000-1, 2005, 2009) African Journal of Microbiology (2013) American Journal of Clinical Nutrition (2004) American Journal of Physiology (1993, 2000) American Journal of Respiratory and Critical Care Medicine (2002) Archives of Pediatric and Adolescent Medicine (2008) British Journal of Nutrition (2009) Clinical Endocrinology (2001) Clinical Medicine and Research (2012) Clinical Nutrition (2011-12) Clinical Orthopaedics & Related Research (2009) Diabetes (1989-91, 2001, 2004, 2005-6, 2008-10, 2013) Diabetes and Metabolism (2012) Diabetes Care (1995, 1997, 2000-2, 2005-6, 2008-13) Diabetic Medicine (2004, 2006-7, 2010, 2012-14) Diabetes Metabolism Research and Reviews (2013) Diabetes Research and Clinical Practice (2004) Diabetes Technology & Therapeutics (2012) Diabetologia (2003-4, 2009, 2012-13) Endocrine Practice (2004) European Journal of Endocrinology (1996, 2009-11) European Journal of Pediatrics (2005) European Respiratory Journal (2008) Expert Opinion On Pharmacology (2009) Hormone and Metabolic Research (1997) Hormone Research in Pediatrics (2008-10) Journal of Clinical Endocrinology and Metabolism (2004-5, 2007, 2013) Journal of Clinical Investigation (2010) Journal of Cystic Fibrosis (2005-7, 2009, 2011-13) Journal of Diabetes and its Complications (2010) Journal of Endocrinological Investigation (2005, 2008) Journal of Medical Genetics (2004)

Updated 2/11/2014

7

Journal of Pediatric Endocrinology and Metabolism (2006-7, 2011) Journal of Pediatric Gastroenterology and Nutrition (1993, 2001) Journal of Pediatrics (1996-7, 2001-10) Lancet (2013) Metabolism (1992) Nature Reviews, Endocrinology (2010) New England Journal of Medicine (2001) Nutrition, Metabolism and Cardiovascular Diseases (2008) Pediatric Diabetes (2002-4, 2007-10, 2012-14) Pediatric Pulmonology (2012-13) Pediatric Research (2001, 2006) Pediatrics (1994, 1997, 2013) PNAS (2010) Respiratory Care (2012) Respirology (2009) Thorax (2006, 2010)

Research Grants and Awards CURRENT NIH U01-DK085476 Type 1 Diabetes - A Proposal for Prevention (TrialNet) Role: PI Annual Direct Costs $922,687; 9/30/09-4/30/2014 PO #0000161342 University of South Florida Type 1 Diabetes TrialNet Clinical Affiliate Role: PI Annual Direct Costs $136,040; 9/30/09-4/30/2014 N01-AI-15416 NIH Immune Tolerance Network (Gitelman, UCSF prime) ATG for new Onset T1D Role: Site PI Project Total Direct Costs $422,860 (capitated); 10/1/2007-4/30/2014 N01-A1-15416 NIH Immune Tolerance Network (Bluestone, UCSF prime) Preserving Beta Cell Function with Tocilizumab in New Onset Type 1 Diabetes Role: Site PI Annual Direct Cost-$21,055 (start-up); 10/1/2013-4/30/2014 PO 2R2-N-2967897 Pfizer, Inc Pfizer type 1 diabetes drug development—a preliminary laboratory study. Role: PI

RESEARCH

Updated 2/11/2014

8

Annual Direct Costs: $44,030; 8/2011-9/2014 NIH K23DK083551 (Blackman, Prime, Johns Hopkins) Genetic Modifiers of Cystic Fibrosis Related Diabetes Role: Sub-award PI Annual Direct Costs $19,875; 2/13/13-12/31/2013 NIH R24DK096518 (University of Iowa, Engelhardt, Prime) Early Pathogenesis of cystic fibrosis related diabetes Role: Sub-award PI Annual Direct Costs $122,583; 8/15/12-8/14/2015 S889774 Cystic Fibrosis Foundation(Philips, Emory University prime) Practical two-step screening for CFRD and prediabetes Sub-award PI: Moran $238,289; 7/1/12-6/30/15 AIN457A 2227 Novartis Pharmaceuticals Corporation A randomized, double-blind, multiope dose, pacebo-controlled trial of sekucinumab in new onset type 1 diabetes Role: Site PI $375,730 direct (capitated), 8/17/2012-3/1-2018 Jaeb Center for Health Research Foundation (Helmsley Trust, Prime) T1D Exchange Role: Site PI 12/2010-2/2012; Co-investigator 3/2012-2/28/2014 Project Total Direct Costs: $91,250 (capitated), 12/6/2010-2/28/2014 CURRENT TRAINING GRANTS CTSI Fellowship Project Grant Role: Sponsor Trainee Tanya Halvorson, MD Project Direct Costs: $5000; 11/1/2013-10/31/2015 ISPAD Drash Fellowship Role: Sponsor Trainee Teresa Piloya, MD, Makerere University, Uganda Project Direct Costs: $5000; 7/1/2014-9/1/2014 NICHD K12 HD068322 Bedside to Bench and Back Again: Training Pediatricians in Translational Research Role: Recruiting Officer (PI-Neglia) Annual direct Costs: $398, 850; 12/30/2010-11/30/2015 NIDDK T32 DK065519 Pre-Faculty Research Training in Pediatric Endocrinology Role: PI Annual Direct Costs $183,294; 7/1/09-6/30/2014

Updated 2/11/2014

9

Funded since 2004 PAST AWARDS NIH Immune Tolerance Network N01-A1-15416 (UCSF prime) ITN045A1: Inducing remission in new onset T1D with alefacept (Amevive) Role: Site PI Project Total Direct Costs $202,833 (capitated); 4/1/2011-4/30/2014 Merck Sharp & Dohme Corp A double-blind, randomized, placebo controlled intervention study to assess the impact of sitagliptin on insulin independence following pancreatectomy and autoislet transplantation. Role: PI Annual direct Costs: $2500; 10/2010-7/31/2012 GlaxoSmithKline (TRX4-DM-018-US-10) DEFEND 2: Durable response therapy evaluation for early or new onset T1D Role: PI Project Total Direct Costs $16,990, 8/2010-7/2013 GlaxoSmithKline (TRX4-DM-005-NA-06) TTEDD: TRX4 therapeutic evaluation of different multi-dose regimens in T1D Role: PI Project Total Direct Costs (capitated) $641,310, 2/17/2010-2/29/2013 Osiris Therapeutics, Inc. A Phase II Study of PROCHYMAL (ex vivo cultured adult human mesenchymal stem cells) for the Treatment of Recently Diagnosed T1D. Role: PI Project Total Direct Costs $174,231 (capitated), 9/19/2008-6/30/2012 NCI/NIDDK, 1RO1CA113930 Metabolic syndrome in childhood cancer survivors Role: Co-Investigator (PI: Steinberger) Annual Direct Costs $366,157; 4/06-2/28/2012 NCI/NIDDK, 1RO1 DK072124 Cardiovascular Risk and Insulin Resistance: Age 7-40 Role: Co-Investigator (PI: Steinberger) Annual Direct Costs $392,296; 07/01/2007 - 12/31/2011 Benaroya Research Institute at Virgina Mason Type 1 Diabetes Genetics Consortium PI: Antoinette Moran (1%) $70,775; 1/04-12/09 NIH R01 HL52851 Influence of Insulin on BP Change in Adolescence PI: Alan Sinaiko

Updated 2/11/2014

10

Co-investigator: Antoinette Moran (10%) $458,739, 6/95-5/2004; $2,490,144, 6/04-5/09 Cystic Fibrosis Foundation Insulin Therapy to Improve BMI and Pulmonary Function in Cystic Fibrosis PI: Antoinette Moran (5%) $129,600; 7/06-12/07 Juvenile Diabetes Foundation USCF – U of M Center Grant, Islet Transplantation PI: Bernhard Hering Core D (Metabolism) Core Leader: Antoinette Moran (2%) $3,479,065 ; 2/1/2004-1/31/2009 Juvenile Diabetes Research Foundation The Islet Sanctuary PI: Bernhard Hering Coinvestigator: Antoinette Moran (1%) $605,009; 11/05-10/08 NIH R01 DK56963 Tolerance to Islet Allografts in Type 2 Diabetes PI: Bernhard Hering Coinvestigator: Antoinette Moran (2%) $3,554,492; 9/1/03-8/31/06; NIH R01DK58356-01A1 Insulin Therapy to Improve BMI and Pulmonary Function in Cystic Fibrosis PI: Antoinette Moran (20%) $3,652,893; 7/01-5/07 Cystic Fibrosis Foundation Intensive insulin therapy in the hospitalized CF patient: A pilot study. PI: Antoinette Moran (5%) $111,789; 4/1/05-9/30/07; Juvenile Diabetes Research Foundation Research Fellowship in Diabetes Sponsor: Antoinette Moran; Recipient: Irene Hong-McAtee $52,492; 5/1/05-4/31/06 LWPES/ Juvenile Diabetes Research Foundation Research Fellowship in Diabetes (NMR Studies of Human Brain Glucose Metabolism) Sponsor: Antoinette Moran; Recipient: Amy Criego $164,998; 8/1/02-7/31/05 Aventis Pharmaceuticals Insulin Glargine vs Standard Therapy in Cystic Fibrosis Related Diabetes PI: Antoinette Moran

Updated 2/11/2014

11

$135,700; 10/02-12/05 Cystic Fibrosis Foundation Microvascular Complications in Cystic Fibrosis Related Diabetes PI: Antoinette Moran $259,981; 4/01-3/05 Cystic Fibrosis Foundation Improving the Detection and Management of Cystic Fibrosis Related Diabetes PI: Ted Liou Consultant: Antoinette Moran $289,984; 7/02-6/04 Vikings Children's Fund Microvascular Complications in Cystic Fibrosis Related Diabetes PI: Antoinette Moran $10,500; 1/01-12/01 Minnesota Medical Foundation Insulin Absorption in Cystic Fibrosis PI: Antoinette Moran $5000; 1/00-12/00 Novo Nordisk Pharmaceuticals Insulin Therapy to Ameliorate Protein Catabolism in Cystic Fibrosis PI: Antoinette Moran $150,000; 1/00-12/00 Cystic Fibrosis Foundation Insulin Therapy to Ameliorate Protein Catabolism in Cystic Fibrosis PI: Antoinette Moran $289,727; 4/99-3/2001 Minnesota Medical Foundation The Effect of Insulin on Protein Metabolism in Infants PI: Antoinette Moran $12,500; 12/98-11/99 Vikings Children's Fund Insulin Therapy to Ameliorate Protein Catabolism in Cystic Fibrosis PI: Antoinette Moran $10,000; 6/97-6/98 Cystic Fibrosis Foundation Substrate Utilization in Cystic Fibrosis PI: Antoinette Moran $150,000; 12/96-11/98

Updated 2/11/2014

12

Cystic Fibrosis Foundation Insulin Therapy and Protein Catabolism in Cystic Fibrosis PI: Antoinette Moran $162,000; 4/96-3/99 Vikings Children's Fund Insulin Deficiency and Protein Catabolism in Cystic Fibrosis PI: Antoinette Moran $9000; 6/95-6/96 Vikings Children's Fund Comparison of Dietary High-Calorie Supplements in Cystic Fibrosis PI: Antoinette Moran $2,400; 6/93- 5/94 Cystic Fibrosis Foundation Insulin Sensitivity and Clinical Response in Cystic Fibrosis PI: Antoinette Moran $289,765; 7/91-6/94 Vikings Children Fund Hyperinsulinemic Euglycemic Clamp Evaluation of Insulin Sensitivity in Cystic Fibrosis PI: Antoinette Moran $6,660; 6/91-5/92 Minnesota Medical Foundation The Role of Glucose Concentrations and Growth Factors in Diabetic Nephropathy PI: Antoinette Moran $4,500; 6/90-6/91 NIH U01 DK 30626 Diabetes Control and Complications Trial (DCCT) PI: John Bantle Co-investigator: Antoinette Moran, 30% effort 7/89-7/93 Vikings Children's Fund The Role of Hyperglycemia and Growth Factors in Diabetic Nephropathy PI: Antoinette Moran $9,596; 6/89-5/90 Cystic Fibrosis Foundation Diabetes and Cystic Fibrosis PI: Antoinette Moran $90,500; 7/88-6/91 Peer-Reviewed Publications

Updated 2/11/2014

13

1. Moran A, MacDonald J. Eight cases of childhood stroke. Minnesota Medicine 68:675-7, 1985.

2. Klein DJ, Brown DM, Moran A, Oegema TR, Platt J. Chondroitin sulfate proteoglycan synthesis and reutilization of beta-D-xyloside initiated chondroitin/dermatan sulfate glycosaminoglycans in fetal kidney branching morphogenesis. Dev. Biol. 133:515-28. 1989.

3. Moran A, Asa SL, Horvath E, Kovacs K, Horvath E, Winger W, Sagman U, Reubi JC, Wilson CB, Larson R, Pescovitz OH. Gigantism due to pituitary mammostomatotroph hyperplasia. N Engl J Med 323: 322-327. 1990

4. Diem P, Redmon JB, Abid M, Moran A, Sutherland DER, Halter JB, Robertson RP. Glucagon, catecholamine and pancreatic polypeptide secretion in type I diabetic recipients of pancreas allografts. J Clin Invest 86:2008-2013. 1990.

5. Moran A, Diem P, Levitt M, Klein DJ, Robertson RP. Pancreatic endocrine function in cystic fibrosis. J Pediatr 118: 715-23, 1991.

6. Moran A, Brown DM, Kim YK, Klein DJ. The effects of IGF-I and hyperglycemia on protein and proteoglycan synthesis by human fetal mesangial cells. Diabetes. 40:1346-54, 1991.

7. Shenker A, Weinstein LS, Moran A, Pescovitz OH, Charest NJ, Van Wyk JJ, Merino MJ, Feuillan PP, Spiegel AM. Severe non-endocrine manifestations of the McCune-Albright syndrome associated with activating mutations of the stimulatory G protein Gs. J. Pediatr. 123:509-18, 1993.

8. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-86, 1993.

9. Moran A, Pescovitz OH. Long-term treatment of gigantism with combination octreotide and bromocriptine therapy in a child with McCune-Albright syndrome. Endocrine Journal 2:111-3, 1994.

10. Moran A, Pyzdrowski K, Weinreb J, Kahn BB, Adams K, Seaquist ER. Insulin sensitivity in cystic fibrosis. Diabetes 43:1020-26, 1994.

11. Seaquist E, Pyzdrowski K, Moran A, Robertson RP. Insulin-mediated and glucose-mediated glucose uptake are maintained following hemipancreatectomy in healthy human donors. Diabetologia, 37:1036-43, 1994.

12. Couce M, O'Brien TD, Moran A., Roche PC, Butler, PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J. Clin Endocrinol. Metab. 81: 1267-72, 1996.

13. Milla C, Doherty L, Raatz S, Regelmann W, Schwarzenberg SJ, Moran A. The glycemic response to dietary supplements in cystic fibrosis is dependent upon the carbohydrate content of the formula. J Parenteral Enteral Nutr. 20: 182-6, 1996.

14. Moran A, Zhang H-J, Olson KL, Poitout V, Robertson RP. Differentiation of glucose toxicity from beta cell exhaustion in the pancreatic islet cell line, HIT-T15. J Clin Invest 99:534-9, 1997.

15. Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabolism in cystic fibrosis. J Pediatr. 133:10-17, 1998

16. Dave-Sharma W, Wilson RC, Harbison MD, Newfield, R, Rassaghy-Azar M, Krozowski ZS, Funder JW, Shackleton CHL, Bradlow HL, Wei J-Q, Hertecant J, Moran A, Neiberger RE, Balfe JW, Fattah A, Daneman D, Akkurt HI, Di Santis C, New MI. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 83:2244-54. 1998

Updated 2/11/2014

14

17. Moran A, chair, and the consensus committee. Guidelines for the diagnosis, screening and management of cystic fibrosis related diabetes. Diabetes Research and Clinical Practice, 45: 55-71, 1999.

18. Moran A, Steinberger J, Jacobs D, Hong C-P, Prineas R, Luepker R, Sinaiko AR. Insulin resistance during puberty: results from insulin clamp studies in 356 children. Diabetes, 48: 2039-44. 1999

19. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in cystic fibrosis patients correlate with the results of oral glucose tolerance test at baseline. Am J Resp Crit Care Med. 162:891-5, 2000

20. Moran A. Cystic fibrosis related diabetes: an approach to diagnosis and management. Pediatric Diabetes, 1: 41-8, 2000.

21. Moran A , Milla C, Ducret R, Nair SK. Protein metabolism in clinically stable adult cystic fibrosis patients with abnormal glucose tolerance. Diabetes, 50: 1336-43, 2001.

22. Steinberger J, Moran A, Hong C-P, Jacobs DR, Sinaiko AR. Adiposity in childhood predicts obesity and insulin resistance in young adulthood. J Pediatr, 138:469-73, 2001.

23. Moran A, Phillips, J, Milla C. Insulin and glucose excursion following pre-meal insulin lispro or repaglinide in cystic fibrosis related diabetes. Diabetes Care, 24:1706-10, 2001.

24. Sinaiko A, Jacobs DR, Steinberger J, Moran A, Luepker R, Rocchini AP, Prineas, RJ. Insulin resistance syndrome in childhood: associations of the euglycemic insulin clamp and fasting insulin with fatness and other risk factors. J Pediatr. 139:700-7, 2001.

25. Keenan J, Pins J, Frazel C, Moran A, Turnquist L. Oat ingestion reduces systolic and diastolic blood pressure in patients with mild or borderline hypertension: a pilot trial. 2002, J Family Practice, 51:369.

26. Figueroa V, Milla C, Schwarzenberg SJ, Parks E, Moran A. Abnormal lipid levels in cystic fibrosis. American Journal of Clinical Nutrition, 75:1005-11, 2002.

27. Steinberger J, Jacobs DR, Moran A, Hong C-P, Rocchini AP, Prineas RJ, Sinaiko AR. Relation of insulin resistance and body composition to left ventricular mass in children. 2002, Am J Cardiol, 90:1177-1180.

28. Sinaiko AR, Steinberger J, Moran A, Prineas RP, Jacobs DR. Relations of insulin resistance to blood pressure in childhood. J Hypertens 20:509-17, 2002.

29. McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS in patients with tightly controlled type 1 diabetes. Diabetes Care 25:1499-1503. 2002.

30. Moran A, Jacobs RD, Steinberger J, Cohen P, Hong CP, Prineas R, Sinaiko AR. Association between the insulin resistance of puberty and the IGF-I/ growth hormone axis. J Clin Endocrinol Metab, 87:4817-20, 2002.

31. Schmitz KH, Jacobs DR, Hong CP, Steinberger J, Moran A, Sinaiko A. Association of physical activity with insulin sensitivity in children. Int J Obesity: 26:1310-6, 2002

32. Borowitz D, Baker RD, Stallings V, Bachrach LK, Beall RJ, Campbell PW, Casey SC, Cohen MB, Corey M, Hobart Davies W, Fulton JA, Grand RJ, Grunow JE, Hardin DS, Hendeles L, Heubi JE, Hubbard VS, Kai H-C, Innis S, Luder E, MacGuiness K, Mathis RK, McKenna A, Moran A, Moyer-Mileur L, O’Brien KO, Quinton H, Quittell LM, Shepherd RW, Sokol RJ, Stark LJ, Udall JN, Zemel B. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Ped Gastroenterol Nutr 35:246-59, 2002.

33. Steinberger J, Steffen L, Jacobs DR, Moran A, Hong C-P, Sinaiko AR. The relations of leptin to the insulin resistance syndrome in children. Obesity Research, 11:1124-30, 2003.

Updated 2/11/2014

15

34. Murtaugh MA, Jacobs DR, Moran A, Steinberger J, Sinaiko AR. Relation of birth weight to fasting insulin, insulin resistance, and body size in adolescence, 2003 Diabetes Care 26:187-192.

35. Steffen LM, Jacobs DR, Murtaugh MA, Moran A, Steinberger J, Hong C-P, Sinaiko AR. Whole grain intake is associated with lower body mass and greater insulin sensitivity among adolescents. Am J Epidemiol, 158:243-50, 2003.

36. Jackson A, Ternand C, Brunzell C, Kleinschmidt T, Dew D, Milla C, Moran A. Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes. 2003, 4:64-69, Pediatric Diabetes.

37. Pankow JS, Jacobs DR, Steinberger J, Moran A, Sinaiko AR. Insulin resistance and cardiovascular disease risk factors in children of parents with the insulin resistance syndrome. 2004, 27:775-80, Diabetes Care.

38. Moran A, Basu R, Milla C, Jensen MD. Insulin regulation of free fatty acid kinetics in adult cystic fibrosis patients with impaired glucose tolerance. 2004, 53:1467-72, Metabolism.

39. Marshall BC, Butler SM, Stoddard M, Moran A, Liou TG, Morgan WJ. Epidemiology of cystic fibrosis-related diabetes J Pediatr. 146:681-7, 2005

40. Steinberger J, Jacobs DR, Raatz S, Moran A, Hong C-P, Sinaiko AR. Assessment of body fatness by DXA vs skinfolds and BMI measurements in adolescents. Int J Obesity 29: 1346-52; 2005

41. Sinaiko, AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu S, Tracey R, Jacobs DR. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors and oxidative stress during adolescence. Circulation 111:1985-91, 2005.

42. Moran A, Jacobs DR, Tracy R. Steinberger J, Steffen LM, Pankow JS, Hong C-P, Sinaiko AR. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care, 28:1763-8, 2005.

43. Milla CE, Billings J, Moran A. Diabetes is Associated with dramatically decreased survival in women but not men with cystic fibrosis. Diabetes Care, 28:2141-44, 2005.

44. Sivanandam S, Sinaiko AR, Jacobs DR, Moran A, Steinberger J. Relation of increase in adiposity to increase in left ventricular mass from childhood to young adulthood. 2006, Am J Cardiol, 98:411-15.

45. Meier JJ, Hong-McAtee I, Galasso R, Veldhuis JD, Moran A, Hering B, Butler PC. Intra-hepatic transplanted islets in humans secrete insulin in a coordinate pulsatile manner directly into the liver. Diabetes 55:000-000, 2006

46. Sinaiko AR, Steinberger J, Moran A, Hong CP, Prineas, RJ, Jacobs DR. Influence of insulin resistance and BMI at age 13 on levels of systolic blood pressure, triglycerides, and HDL-C at age 19. Hypertension, 48:730-36, 2006.

47. Schwarzenberg SJ, Grover T, Olsen T, Walk D, Kennedy W, Thomas W, Moran A. Diabetes microvascular complications in cystic fibrosis related diabetes. Diabetes Care, 30:1056-61, 2007

48. Rasmussen-Torvik LJ, Pankow JS, Jacobs, DR, Steffen LN, Moran A, Steinberger J, Leindecker-Foster C, Sinaiko AR. Heritability and genetic correlations of insulin sensitivity measured by the euglycemic clamp. Diabetic Medicine, 24:1286-9, 2007.

49. Greenbaum CJ, Mandrup-Poulsen T, Friedenberg McGee P, Battelion T, Haastert B, Ludvigsson J, Pozzilli P, Lachin JM, Kolb H, the Type 1 Diabetes TrialNet Research Group and the European C-peptide Trial Study Group. Mixed-meal tolerance test versus

Updated 2/11/2014

16

glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31: 1966-71, 2008.

50. Grover T, Moran A. Insulin glargine versus NPH insulin in cystic fibrosis related diabetes. J Cystic Fibrosis, 7:134-6, 2008.

51. Schwartz B, Jacobs DR, Moran A, Steinberger J, Hong C-P, Sinaiko AR. Measurement of Insulin Sensitivity in Children: Comparison between the euglycemic-hyperinsulinemic clamp and surrogate measures. Diabetes Care, 31:783-8, 2008.

52. Moran A, Jacobs DR, Steinberger J, Steffen LM, Pankow JS, Hong C-P, Sinaiko A. Natural history of insulin resistance and cardiovascular risk during adolescence: establishment of differential risk in males and females. Circulation, 117:2329-36, 2008.

53. Bellin M, Carlson AM, Kobayashi T, Gruessner AC, Hering BJ, Moran A, Sutherland DER. Outcomes after pancreatectomy and islet autotransplantation in a pediatric population. J Pediatr Gastroenterol Nutr 47:37-44, 2008.

54. Steffen, LM, Vessby B, Jacobs DR, Steinberger J, Moran A, Hong C-P, Sinaiko AR. Serum Phospholipid and Cholesteryl Ester Fatty Acids and Estimated Desaturase Activities are Related to Overweight and Cardiovascular Risk Factors in Adolescents. Int J Obesity 2008; 32: 1297–1304.

55. O’Riordan S, Robinson RD, Donaghue KC, Moran A. ISPAD Clinical Practice Consensus Guidelines: Management of CFRD. Pediatric Diabetes 9:338-344, 2008

56. Bellin M, Kandaswamy R, Parkey J, Zhang H-J, Liu B, Ihm S-H, Bauer A, Ansite JD, Witson J, Bansal-Pakala P, Balamurugan AN, Papas K, Sutherland DER, Moran A, Hering AJ. Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes. Am J Transplantation 8:2463-70, 2008.

57. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Ratkin-Mervis L, Savage P, Spain L, and the type 1 Diabetes TrialNet Study Group. Type 1 diabetes TrialNet-an international collaborative clinical trials network. Annals of the New York Academic of Sciences 1150:14-24, 2008. PMID 19120262, NIHMS225039

58. Skylar JS and the Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Annals of the New York Academy of Sciences 1150: 190-96, 2008. PMID 19120293, NIHMS225042

59. Mahon J. Sosenko, JM, Ratkin-Mervis LE, Strause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS, for the TrialNet Natural History Committee and Type 1 Diabetes TrialNet Study Group. The TrialNet natural history study of the development of type 1 diabetes: objectives, design, and initial results. Pediatric Diabetes 10:97-104, 2009. PMID 18823409

60. Holt EM, Steffen LM, Moran A, Basu S, Steinberger J, Ross JA, Hong C-P, Sinaiko, AR. Fruit and vegetable consumption and its relation to markers of inflammation and oxidative stress in adolescents. J Am Diet Assoc 109:414-21, 2009.

61. Rasmussen-Torvik LJ,Pankow JS,Jacobs DR,Steinberger J, Moran A, Sinaiko AR. Influence of waist on adiponectin and insulin sensitivity in adolescence.Obesity 17:156-61, 2009

62. Rasmussen-Torvik LJ, Pankow JS, Jacobs DR, Steinberger J, Moran A, Sinaiko AR. The association of SNPs in ADIPOQ, ADIPOR1 and ADIPOR2 with insulin sensitivity in a cohort of adolescents and their parents. Hum Genet 125:22, 2009

63. Polgreen LE, Thomas W, MacMillan ML, Wagner JE, Moran A, Petryk A. First phase insulin release and glucose tolerance in patients with Fanconi anemia after hematopoietic cell transplantation. Pediatric Blood and Cancer, 53:191-6, 2009.

Updated 2/11/2014

17

64. Chase HP, Lescheck E, Rafkin-Mervis L, Krause-Steinrauf H, Chritton S, Asare SM, Adams S, Skyler JS, Clare-Salzler M and the Type 1 Diabetes TrialNet NIP Study Group. Nutritional Intervention to Prevent (NIP) Type 1 Diabetes, A Pilot Trial. Infant, Child and Adolescent Nutrition 1:98-107, 2009.

65. Barrett JC, Clayton, DG, Concannon P, Akolkar B, Cooer JD, Erlich HA, Julier C, Morahan G, Nerup J, Neirras C, Plagnol V, Pocito F, Schuilenburg H, Smyth DJ, Stevens H, Todd JA, Walker NM, Rich SS, and the type 1 Diabetes Genetics Consortium. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nature Genetics, 41:703-7, 2009

66. Luscri N, Mauer M, Sarafoglou K, Moran A, Tolar J. Lactic acidosis and hypoglycemia with ALL relapse following engrafted BMT. Pediatr Blood Cancer 53:223-225, 2009.

67. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. CFRD: Current Trends in Prevalence, Incidence and Mortality. Diabetes Care 32:1626-31, 2009.

68. Moran A, Pekow P, Grover T, Zorn M, Slovis B, Pilewski J, Tullis E, Liou TG, Allen H. Insulin Therapy to Improve BMI in Cystic Fibrosis Related Diabetes Without Fasting Hyperglycemia: Results of the CFRDT Trial. Diabetes Care 32:1783-8, 2009.

69. Herold KC, Brooks-Worrell B, Palmer J, Dosch HM, Peakman M, Gottlieb P, Reijonen H, Arif S, Spain LM, Thompson C, Lachin JM, and the Type 1 Diabetes TrialNet Research Group. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes, 58:2588-95, 2009.

70. Pescovitz M, Greenbaum CJ, Krause-Steinrauf H, Gitelman WE, Roland R, Gottlieb P, Marks JB, McGee P, Moran A, Raskin P, Rodriquez H, Schatz DA, Wherrett D, Wilson D, Lachin JM, Skyler JS. Preservation of beta-cell function by B-lymphocyte depletion with rituximab in patients with new onset autoimmune diabetes. N Engl J Med 361:2143-52, 2009

71. Kobayashi T, Manivel JC, Bellin M, Carlson A, Moran A, Hering B, Sutherland DER. Correlation of histopathology of excised pancreas and islet yield in children with chronic pancreatitis. Pancreas, 39:57-63, 2010.

72. Gottlieb, PA, Quinlan S, Krause-Steinrauf H, Greenbaum C, Wilson D, Rodriquez, H, Schatz D, Moran A, Lachin J, Skyler J. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new onset type 1 diabetes. Diabetes Care, 33:826-32, 2010. PMID 20067954, PMC2845036.

73. Bellin DM, Blondet J, Beilman G, Thomas, W, Suthland DER, Moran A. Predicting islet yield in pediatric patients undergoing pancreatectomy and autoislet transplantation for chronic pancreatitis. Pediatric Diabetes, 11: 227-34, 2010.

74. Kelly A, Hebbel RP, Solovey AN, Schwarzenberg SJ, Metzig AM, Moran A, Sinaiko AR, Jacobs DR, Steinberger J. Circulating activated endothelial cells in pediatric obesity, J Pediatr: 157:547-51, 2010.

75. Ode KL, Frohnert B, Laguna T, Phillips J, Holmes B, Regelmann W, Thomas W, Moran A. Oral Glucose Tolerance Testing in Children with Cystic Fibrosis. Pediatric Diabetes, 11:487-92, 2010.

76. Moran A, Becker D, Casella S, Gottlieb PA, Kirkman MS, Marshall BC, Slovis B. Epidemiology, pathophysiology and prognostic implications of CFRD: a technical review. Diabetes Care, 33:2677-83, 2010.

77. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onaday G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical Care Guidelines for Cystic Fibrosis Related Diabetes: Recommendations from the Cystic Fibrosis Foundation, the American Diabetes Association, and the Pediatric Endocrine Society. Diabetes Care, 33:2697-2708, 2010.

Updated 2/11/2014

18

78. Frohnert B, Ode KL, Moran A, Nathan B, Regelmann W, Dunitz J, Holmes B, Thomas W. 2009. Impaired fasting glucose in cystic fibrosis. Diabetes Care, 33:2660-4, 2010.

79. Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of circulating oxidized LDL with obesity and insulin resistance in children. Pediatric Diabetes, 11:552-5, 2010

80. Dengel D, Jacobs DR, Steinberger J, Moran AM, Sinaiko A. Gender Differences in Vascular Function and Insulin Sensitivity in Young Adults. J Clin Science, 120: 153-60, 2011

81. Huang CJ, Butler AE, Rao N, Wagner J, Blazar B, Rizza RA, Moran A, Manivel JC, Butler PC. A low frequency of pancreatic islet insulin expressing cells derived from cord blood stem cell allografts in in humans. Diabetologia, 54:1066-74, 2011.

82. Orban T, Bundy B, Becker DJ, DiMeglio L, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Rodriguez H, Russell WE, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, and the T1D TrialNet Abatacept Study Group. Preservation of beta-cell function by T-lymphocyte co-stimulation blockade with abatacept in patients with recent onset type 1 diabetes mellitus. Lancet, 378:412-19, 2011. PMID 21719096

83. Wherrett D, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Herold KC, Lachin JM, Marks JB, Monzavi R, Moran A, Orban T, Palmer JP, Raskin P, Rodriguez H, Schatz D, Wilson DM, Krischner JP, Skyler JS, and the T1D TrialNet GAD Study Group. Antigen-based therapy with Glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomized double-masked controlled trial. Lancet, 378:319-27, 2011. PMID 21714999

84. Kelly AS, Steinberger J, Jacobs DR, Hong C-P, Moran A, Sinaiko AR. Predicting cardiovascular risk in young adulthood from metabolic syndrome, its component risk factors and a cluster score in adolescence. Int J Pediatr Obes, 2011;6(2-2):e283-289

85. Bellin MD, Freeman M, Schwarzenberg SH, Dunn T, Beilman G, Vickers SM, Chinnakotla S, Balamurugan AN, Hering BJ, Radosevich DM, Moran A, Sutherland DER. Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. Clinical Gastroenterology and Hepatology,9:793-99 2011

86. Pescovitz MD, Torgerson TR, Ochs HD, Ocheltree E, McGee P, Krause-Steinrauf H, Lachin JM, Canniff J, Greenbaum C Herold KC, Skyler JS, Weinberg A and the Type 1 Diabetes TrialNet Study Group (AMoran, member). Effect of Rituximab on Human In Vivo Antibody Immune Responses. J Allergy Clin Immunol 128:1295-1302, 2011. PMID 21908031, PubMed in process.

87. Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP for the TrialNet Natural History Study Group (Moran, member). Development of Autoantibodies in the TrialNet Natural History Study (NHS). Diabetes Care 34:1897-1901, 2011. PMID 21750277, PMC3161292

88. Herold K, Pescovitz M, McGee P, Krause-Steinrauf H, Spain L, Bourcier K, Asare A, Liu Z, Lachin J, Dosch HM, for the Type 1 Diabetes TrialNet Study Group (A Moran, member). Increased T Cellular Proliferative Responses to Islet Antigens Identify Clinical Responders to Anti-CD20 Monoclonal Antibody (Rituximab) Therapy in Type 1 Diabetes. J Immunology, 187:1998-2005, 2011. PMID 21775681, PMC3150302, NIHMS303803

89. Yu L, Herold K, Lachin J, Bundy B, Pugliese A, Krischer J, Eisenbarth G, Pescovitz M, Type 1 Diabetes TrialNet Anti-CD20 Study Group (A Moran, member). Rituximab

Updated 2/11/2014

19

Selectively Suppresses Specific Islet Antibodies. Diabetes, 60: 2560-5, 2011. PMIC21831969, PMC3178300

90. Mahon JL, Beam CA, Marcovina SM, Boulware DC, Palmer UP, Winter William E, Skyler JS, Krischer JP and the Type 1 Diabetes TrialNet Study Group (A Moran, member). Comparison of Two Insulin Assays for First-Phase Insulin Release in Type 1 Diabetes Prediction and Prevention Studies. Clinica Chimica Acta, 412:2128-31, 2011. PMID 21843518, PMC3150302, NIHMS303803

91. Sosenko JM, Mahon J, Rafkin-Mervis L, Lachin JM, Krause-Steinrauf H, Krischer J, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS, and the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1) and Type 1 Diabetes TrialNet Study Groups (Moran, member). A Comparison of the Baseline Metabolic Profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study Participants. Pediatric Diabetes 12:85-90, 2011

92. Lind-Ayres M, Mauer M, Thomas W, Holm B, Caramori L, Moran A. Microalbuminuria in cystic fibrosis patients. Diabetes Care 34:1526-8, 2011.

93. Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP and the TrialNet and Diabetes Prevention Trial–Type 1 Study Groups (Moran, member). Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care, 34:1785-7, 2011.

94. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering M, Schwartz BL, Abuzzahab MJ, Gandrud LM, Moran A, Billington CJ, Schwarzenberg SJ. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity 2012;20(2):364-370

95. Lachin J, Friedenberg-McGee P, Greenbaum CJ, Spain L, Palmer J, Pescovitz MD, Gottlieb P, Skyler J, for the Type 1 Diabetes TrialNet Study Group (Moran, member). Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Diabetes. PLOS One 6(11): e26471. PMID 22102862

96. Kobayashi T, Manivel C, Carlson A, Bellin MD, Moran A, Hering B, Sutherland D. Correlation of histopathology, islet yield, and islet graft function after islet autotransplantation in chronic pancreatitis. Pancreas, 2011; 40(2):193-9

97. Bellin MD, Hong-McAtee I, Sutherland D, Balamarugan AN, Hering B, Moran A. Similar islet function in alloislet and autoislet transplant recipients, despite the lower mass of islet autotransplants. Transplantation, 2011;91(3):367-72

98. Frohnert BI, Sinako AR, Serot F, Foncea R, Moran A, Ikramuddin S, Choudry U, Bernlohr, D. Increased adipose protein carbonylation in human obesity. Obesity, 2011; 19:1735-41

99. Wang H, Steffen LM, Vessby B, Basu S, Steinberger J, Moran A, Jacobs DR, Hong C-P, Sinaiko, AR. Obesity modifies the relations between markers of dairy fats and inflammation and oxidative stress in adolescents. Obesity 2011; 19:2404-2410

100. Steinberger J, Sinaiko A, Kelly A, Leisenring W, Steffen L, Goodman P, Mulrooney D, Dietz A, Moran A, Perkins J, Norris A, Frohnert B, Lunsford Lee J, Baker S. Cardiovascular risk and insulin resistance in childhood cancer survivors. Journal of Pediatrics, 2011; 160:494-9

101. Rasmussen-Torvic, LJ, Pankow JS, Jacobs DR, Steinberger J, Moran A, Sinaiko A. Development of associations among central adiposity, adiponectin and insulin sensitivity from adolescence to young adult hood. Diabetic Medicine 29: 1153-8, 2012

102. Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon J for the Type 1 Diabetes TrialNet Study Group (Moran A, member). Zinc Transporter-8autoantibodies improve

Updated 2/11/2014

20

prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care, 35:1213-18, 2012. PMID 22446173, PMC3357246

103. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM, for the Type 1 Diabetes TrialNet Study group (Moran A, member). Fall in C-peptide over first two years from diagnosis: evidence of at least two distinct phases from composite TrialNet data. Diabetes 61:2066-73, 2012 PMID 22688329, PMC3402330

104. Sosenko JM, Skyler JS, Mahon J, Krishcher JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP, for the TrialNet and Diabetes Prevention Trial-Type 1 Study Groups (Moran A member). The application of the diabetes prevention trial risk score (CPTRS) for identifying a pre-clinical state of type 1 diabetes. Diabetes Care 35:1552-5, 2012, PMID 22547092, PMC3379597

105. Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers M, Schatz DA, Krischer JP, and the TEDDY, TRIGR, Diabetes Prevention Trial-Type 1 and Type 1 Diabetes TrialNet Natural History Study Groups (Moran A, member). Performance of Glycated Hemoglobin (HbA1c) as an Early Diagnostic Indicator of Type 1 Diabetes in Children and Youth. Diabetes Care 35:1821-5, 2012 PMID 22699293, PMC3425003

106. Polgreen LE, Nathan B, Jacobs DR, Moran A, Sinaiko AR. Association of osteocalcin with obesity, insulin resistance, and cardiovascular risk factors in young adults. Obesity 20: 2194-220, 2012

107. Gottlieb PA, Yu L, Babu S, Wenzlau J, Bellin M, Frohnert BI, Moran A. No relation between cystic fibrosis related diabetes and type 1 diabetes autoimmunity. Diabetes Care 35, e57, 2012.

108. Petryk A, Baker KS, Frohnert B, Moran A, Sinaiko AR, Steffen LM, Perkins JL, Zhang L, Hodges JS, Steinberger J. Blunted response to a growth hormone stimulation test is associated with unfavorable cardiovascular risk profile in childhood cancer survivors. Pediatr Blood Cancer 2013; 60: 467-473. [PMC3529966].

109. Ognjanovic S, Jacobs DR, Steinberger J, Moran A, Sinaiko AR. Relation of chemokines to BMI and insulin resistance at age 18-21. International Journal of Obesity. 2013; 37:420-23.

110. Sunni M, Bellin M, Moran A. Exogenous insulin requirements do not differ between youth and adults with cystic fibrosis related diabetes. Pediatric Diabetes, 14:295-8, 2013.

111. Bellin MD, Laguna T, Leschyshyn J, Regelmann W, Dunitz J, Billings J, Moran A. Proof-of-concept pilot: insulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR. Pediatric Diabetes 14:417-21, 2013.

112. Moran A, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Greenbaum CJ, Herold KC, Marks JB, Raskin P, Russell WF, Sanda S, Schatz D, Wherrett D, Wilson DM, Krischer JP, Skyler JS, and the T1D TrialNet Canakinumab Study Group and Pickersgill L, de Koning E, Ziegler A, Bohm B, Badenhoop K, Schloot N, Nielsen JB, Pozzilli P, Mauricio D, Donath MY, Castano L, Wagner A, Lervang HH, Perrild H, Mandrup-Poulsen T and the AIDA Study Group. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicenter, randomized, double-masked, placebo-controlled trials. Lancet 381:1905-15, 2013. PMID 23562090

113. Loechelt BJ, Boulware D, Green M, Baden LR, Gottlieb P, Krause-Steinrauf H, Weinberg A for the Type 1 Diabetes TrialNet Daclizumab/Mycophenolic Acid Study Group (Moran, member). Epstein Barr & Other Herpesvirus Infections in Patients with Early Onset Type

Updated 2/11/2014

21

1 Diabetics Treated with Daclizumab & Mycophenolic Mofetil. Clinical Infectious Diseases 2013; 56:248-254. PMID 23042974

114. Mukama LJ, Moran A, Nyindo M, Philemon R, Msuya L. Improved glycemic control and acute complications among children with type 1 diabetes mellitus in Moshi Tanzania. Pedatric Diabetes 2013: 14:211-6.

115. Kroll JL, Beam C, Li S, Viscidi R, Pescovitz M, Weinberg A, the Type 1 Diabetes TrialNet Anti CD-20 Study Group (Moran, member). Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. J Clin Virol 2013;57:115-119. PMID 23422292. PMCID: PMC3640764.

116. Rigby MR, DeMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore VW, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim H, Phippard D, Nepom, GT, McNamar J, Ehlers MR. Targeting effector memory T cells with alefacept in new onset type 1 diabetes: 12 month results from the T1DAL study. Lancet Sept 23, 2013 http://dx.doi.org/10/1016/S2213-8587(13)70111-6

117. Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G, the Type 1 Diabetes TrialNet (Moran, member) and the Diabetes Prevention Trial-Type 1 Study Groups. The Prediction of Type 1 diabetes by multiple autoantibody levels and their incorporation into an sutoantibody risk score in relatives of type 1 diabetes patients. Diabetes Care 2013;36:2615-2620. PMID 23818528. PMID: PMCID: PMC in process.

118. Krischer JP, the Type 1 Diabetes TrialNet Study Group (Moran, member). The use of intermediate endpoints in the design of type 1 diabetes prevention trials. Diabetologia 2013;56:1919-1924. PMID 23744306, PMCID: PMC in process.

119. Weinberg A, Boulware D, Dighero B, Orban T, for the Type 1 Diabetes Abatacept Study Team (Moran, member). Effect of abatacept on immunogenicity of vaccines in individuals with type 1 diabetes. Vaccine 2013;31:4791-4794. PMID 23962535, PMCID: PMC in process.

120. Pescovitz M, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottieb PA, Marks JP, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Krischer JP, Skyler JS and the Type 1 Diabetes TrialNet Anti-CD20 Study Group. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care 2013, Sept 11 Epub ahead of print. PMID 24026563

121. Gitelman SE, Gottlieb PA, Rigby MR, Felner EI, Willi SM, Fisher LK, Moran A, Gottschalk M, Moore WV, Pinckney A, Keyes-Elstein L, Aggarwal S, Phippard D, Sayre PH, Ding L, Bluestone JA, Ehlers MR, and the START Study Team. Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: a randomized double-blind phase 2 trial. The Lancet Aug 28, 2013, doi:10.1016/S2213-8587(13)70065-2

122. Frohnert BI, Jacobs DR, Steinberger J, Moran A, Steffen LM, Sinaiko AR. Relation between serum free fatty acids and adiposity, insulin resistance and cardiovascular risk from adolescence to adulthood. Diabetes, 2013; 62:3163-9.

123. Lundberg R, Beilman GJ, Dunn TB, Pruett TL, Chinnakotla SC, Radosevich DM, Robertson RP, Ptacek P, Balamurugan AN, Wilhelm JJ, Hering BJ, Sutherland, DER, Moran A, Bellin M. Metabolic assessment of patients with chronic pancreatitis prior to total pancreatectomy and islet autotransplant: Utility, limitations and potential. Am J Transplantation 13: 2664-71, 2013

124. Orban T, Bundy B, Becker DJ, DiMeglio LA, Gitelman SE, Goland R, Gottlieb PA, Greenbaum CJ, Marks JB, Monzavi R, Moran A, Raskin P, Russell WE, Schatz D,

Updated 2/11/2014

22

Wherrett D, Wilson DM, Krischer JP, Skyler JS, the Type 1 Diabetes TrialNet Abatacept Study Group. Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-up One Year After Cessation of Treatment. Diabetes Care, December 2, 2013 Epub ahead of print. PMID 24296850

125. Marlatt KL, Steinberger J, Dengel DR, Sinaiko A, Moran A, Chow LS, Steffen LM, Zhou X, Kelly AS. Impact of pubertal development of endothelial function and arterial elasticity. J Peds 163:1432-36, 2013

126. Baker KS, Chow E, Goodman P, Leisenring W, Dietz AC, Perkins J, Chow L, Sinaiko A, Moran A, Petryk A, Steinberger J. Impact of treatment exposures on cardiovascular risk and insulin resistance in childhood cancer survivors. Cancer Epidemiology, Biomarkers & Prevention. 2013;22:1954-1963. [PMC3818503]

127. Steffen LM, Sinaiko AR, Zhou X, Moran A, Jacobs DR, Korenfeld Y, Dengel DR, Chow L, Steinberger J. Relation of adiposity, television and screen time in offspring to their parents. BMC Pediatrics 13:133-141, 2013

128. McCauley LOA, Thomas W, Laguna TA, Regelmann RE, Moran A, Polgreen LE. Vitamin D deficiency is associated with pulmonary exacerbations in children with cystic fibrosis. Annals of the American Thoracic Society. In press.

129. Kelly A, Dengel D, Hodges J, Zhang L, Moran A, Chow L, Sinako A, Steinberger J. The Relative Contributions of the Abdominal Visceral and Subcutaneous Fat Depots to Cardiometabolic Risk in Youth. Clinical Obesity, in press 2014 Manuscripts Submitted

130. Moran A, Nathan BM, Laguna T, Dunitz J, Sunni M, Holme B, Thomas W. Predicting future clinical decline from current oral glucose tolerance status in CF. Submitted

131. Apostolidou I, Cingi E, Walk D, Williams D, Haehn, M, Lunos S, Moran A. Increased risk of intraoperative hypotension in patients with cystic fibrosis related diabetes: a pilot study. Submitted

Manuscripts Undergoing Final Editing

132. Bosch TA, Dengel DR, Kelly AS, Sinaiko AR, Moran A, Steinberger J. Visceral adipose tissue measured by DXA correlates highly with measurement by CT and is associated with cardiometabolic risk factors in children and adolescents. In preparation.

133. Slater ME, Ross JA, Kelly AS, Dengel DR, Sinaiko AR, Moran A, Lee J, Perkins JL, Chow SL, Baker KS, Steinberger J. Physical activity and cardiometabolic risk factors in childhood cancer survivors. In preparation.

134. Dreyfus J, Jacobs D, Folsom A, Moran A, Mueller N, Demerath E. Age at menarche and cardiovascular disease in adulthood: the CARDIA study. In preparation.

135. Watkins AN, Kelly AS, Prineas RJ, Marlatt KL, Dengel DR, Sinaiko A, Moran A, Steinberger J. The relationship between wrist circumference in childhood and insulin resistance in adulthood. In preparation.

Invited Book Chapters 1. Phillips J and Moran A. Cystic fibrosis Related Diabetes. In Pediatric Diabetes, Editor: Mark

Sperling, Publisher: Kluwer Academic Publishers, Norwell, MA. 2003. 2. Figueroa V and Moran A. Diabetes Relacionada a Fibrosis Quistica. In Fibrosis Quística,

Editors: Edgardo Segal, Adriana Fernandez, Fernando Rentaría, Publisher: Ediciones Journal, Buenos Aires, Argentina, 2003.

Updated 2/11/2014

23

3. Eugster E and Moran A. Sexual determination, sexual differentiation and puberty. In Endocrine Pathophysiology, Editor: Catherine B. Niewoehner, Publishers: Fence Creek Publishing, Madison, Connecticut. 1998, 2004.

4. Moran A. Cystic fibrosis Related Diabetes. In Pediatric Endocrinology: Mechanisms, Manifestations, and Management, Editors: Ora H. Pescovitz and Erica Eugster, Publisher: Lippincott Williams and Wilkins, Philadelphia, PA.. 2004.

5. Rosenberg B and Moran A. Puberty and Insulin Resistance. In Insulin Resistance in Children and Adolescents, Editors: Denis Daneman and Jill Hamilton, Publisher: Nova Science Publishers, Inc, Hauppauge,NY. 2005.

6. O’Riordan S and Moran A. Cystic Fibrosis Related Diabetes, In Cystic Fibrosis (Oxford Respiratory Medicine Library), Editor: Alex Horsely; Publisher: Oxford University Press, UK. 2010; 2014.

7. Moran A. Cystic Fibrosis Related Diabetes, In Clinical Decision Support: Pediatrics, Editors: McMillan, Barrett, Boney, and Jones; decisionsupportinmedicine.com, 2012, Submitted for electronic publication

8. Nathan B and Moran A. Other specific types of diabetes, In Diabetes in America 3rd Edition, NIDDK, submitted, 2012

Invited Review Articles, Editorials and Miscellaneous Publications 1. Alford, JA, Beall R, Becker D, Clark L, Doershuk C, Dresing R, Holsclaw D, Kappy M,

McPherson C, Moran A, Mueller D, Rosenbloom A, Rosenstein B, Selden R, Stallings V, Warwick W, Zipf W. Consensus conference on cystic fibrosis -related diabetes mellitus. Cystic fibrosis Foundation Consensus Conferences. Vol I, Section IV, pg1-8, 1990.

2. Moran A, Brown DM, Doherty L, Ainslie M, Sane K, Saxena K, Sheridan K, Spencer M, Sockalosky J, Ternand C. Diagnosis, monitoring, and treatment of short stature in children: Twin Cities community standards. The Endocrinologist 5:272-7, 1995.

3. Doherty L, Brown DM, Ainslie M, Eugster E, Hirsch B, Kashtan C, Moran A, Saxena K, Sheridan K, Sockalosky J, Spencer M, Summers CG, Ternand C. Turner syndrome practice guidelines. The Endocrinologist 7:443-447, 1997.

4. Hardin DS and Moran A. Diabetes Mellitus in Cystic fibrosis. Endocrinology and Metabolism Clinics of North America 28:787-800, 1999.

5. Riggs, AC, Seaquest, ER, Moran A. Diagnosis and treatment of diabetes mellitus in patients with cystic fibrosis. Current Opinion in Pulmonary Medicine. 5:378-82, 1999.

6. Hardin D.S., Brunzell C., Schissel K., Schindler T., Moran A. Managing cystic fibrosis related diabetes. An instruction guide for patients and families. Cystic Fibrosis Foundation 1999, 2009.

7. Moran, A. When should hyperglycemia be treated in cystic fibrosis?--reply (letter). J Pediatr 136: 706-7. 2000.

8. Moran A, Sinaiko A. Influence of intrauterine environment on development of insulin resistance. (Invited editorial) J Pediatr 136:567-9, 2000.

9. Moran A. Cystic fibrosis Related Diabetes. Sante Vous Bien (annual publication of the Adult Cystic Fibrosis Committee of Quebec). 2001.

10. Moran A. Cystic fibrosis related diabetes. International Association of Cystic Fibrosis Adults Newsletter. 1 (60):13-18 2001.

11. Moran A. Diagnosis, Screening and Management of Cystic Fibrosis Related Diabetes. Current Diabetes Reports 2: 111-115, 2002.

12. Moran A. Endocrine complications of cystic fibrosis. In Adolescent Medicine: State of the Art Reviews, "Adolescent Endocrinology". Guest Editor: Peter Lee. 13:145-60. 2002

Updated 2/11/2014

24

13. Moran A and Milla C. Abnormal glucose tolerance in cystic fibrosis: why should patients be screened? (invited editorial). J Pediatr, 2003; 142:97-99.

14. Moran A. Cystic fibrosis-related diabetes: a complication you can manage. Homeline. Cystic Fibrosis Foundation. www.CFServicesPharmacy.com. Winter 2005

15. Moran, A. Of genes and men: the alternative view of sex differences in cystic fibrosis-reply (letter). Diabetes Care 29: 180. 2006.

16. Rosenberg B, Moran A, Sinaiko A. Insulin resistance (metabolic) syndrome in children. Panminerva Medica, 48:229-44, 2006.

17. Nathan B, Moran A. Metabolic complications of obesity in childhood and adolescence: more than just diabetes. Current Opinion in Endocrinology and Diabetes. 15:21-9, 2008.

18. Moran A. Abnormal glucose tolerance in CF---when should we offer diabetes treatment? (invited editorial) Pediatric Diabetes, 10:159-61, 2009.

19. Moran A. Cystic Fibrosis Related Diabetes, In John Hopkins eCysticFibrosis Review, October 2009.

20. Nathan B and Moran A. Diagnosing and Managing Diabetes in Infants (review article); In: US Pediatrics, Volume 5, 2010.

21. Stecenko AA, Moran A. Update on Cystic Fibrosis Related Diabetes. Current Opinion in Pulmonary Medicine 16:611-15, 2010.

22. Laguna T, Nathan B, Moran A. Managing Diabetes in Cystic Fibrosis. Diabetes, Obesity and Metabolism 12: 858-64, 2010.

23. Nathan B, Laguna T, Moran A. Recent trends in cystic fibrosis related diabetes. Current Opinion in Endocrinology and Diabetes 17:335-41, 2010.

24. Nathan B and Moran A. Diabetes Treatment Recommendations for CFRD: Too Little, Too Late? (invited editorial) Thorax 66: 555-6, 2011.

25. Moran A and Brunzell C. CFRD: What you should know. CF Education Day Webcast, Cystic Fibrosis Foundation, www.cff.org. Sept, 2011.

26. Kelly A and Moran A. CFRD. Submitted, Journal of Cystic Fibrosis 2013 27. Sunni M and Moran A. Diabetes in Somali Children. MN Health Care News. October

2013. Invited International Speaking Engagements 1. International Cystic Fibrosis Symposium, plenary speaker, "Diabetes in Cystic Fibrosis ",

Munich, Germany, 9/1996 2. Scottish Cystic Fibrosis Society annual meeting, plenary speaker, "Clinical Physiology of

Diabetes in Cystic Fibrosis ", Sterling, Scotland 5/1997 3. European Cystic Fibrosis Congress, symposium speaker "Diabetes in Cystic Fibrosis ",

Berlin, Germany, 6/1998 4. International Association of Cystic Fibrosis Adults, keynote speaker, "Diabetes in Cystic

Fibrosis” Berlin, Germany, 6/1998 5. European Cystic Fibrosis Congress, symposium speaker, " Cystic Fibrosis Related Diabetes:

When and How to Treat", The Hague, Netherlands, 6/1999 6. KIGS/KIMS Annual Meeting, Clinical Controversies Debate, "Growth Hormone Use in

Cystic Fibrosis: Potential Benefits and Problems", Fajardo, Puerto Rico, 1/2003. 7. European Cystic Fibrosis Congress, symposium speaker, “Early Recognition of Diabetes

Mellitus and When to Start Insulin Replacement Therapy”, Belfast, Northern Ireland 6/2003 8. 10th National Conference of Cystic Fibrosis of the Italian Society of Pediatrics, symposium

speaker, “Nutrition in CF: Role of Diabetes and New Therapies”, Palermo, Italy, 10/2004

Updated 2/11/2014

25

9. Recent Advances and Future Developments in CF Research Seminar, keynote speaker, “Cystic Fibrosis Related Diabetes”, Verona, Italy, 5/2006

10. International Society of Paediatric and Adolescent Diabetes, symposium speaker, “Cystic Fibrosis Related Diabetes”, Cambridge, England, 9/2006

11. Cambridge Institute for Medical Research, invited speaker, “Cystic Fibrosis Related Diabetes”, Cambridge, England, 9/2006

12. Pediatric Academic Society, Meet the Professor lecture, “Building an Academic Career Around Clinical Research”, Toronto, CA 5/2007

13. Mulago Hospital Pediatric Grand Rounds, “Diabetes in Africa”, Kampala, Uganda, 6/2007 14. Canadian Diabetes Association Annual Meeting, symposium speaker, “Cystic Fibrosis

Related Diabetes”, Vancouver, CA, 10/2007 15. ISPAD Post-Graduate Course, faculty: “The Team Approach to Diabetes Management”, and

“The Role of Psychosocial Support in Diabetes Management”, Durban, South Africa 8/2008 16. Ninth Irish National CF Symposium, speaker, “Diabetes in CF”, Killarney, Ireland 1/2009 17. G. Kuppuswamy Naidu Memorial Hospital, special lecture: “The Worldwide Epidemic of

Pediatric Diabetes”, Coimbatore, India, 3/2009 18. India Center for Medical Research, conference speaker: “Pediatric Diabetes and the Potential

for India-US Research Collaboration”, New Delhi, India, 3/2009 19. Lawson Wilkins Pediatric Endocrine Society / European Society for Pediatric Endocrinology

Joint international meeting, symposium speaker: “Insulin insufficiency as a cause of malnutrition in cystic fibrosis”, New York, 9/2009

20. Children’s Hospital of Winnipeg Grand Rounds, “Pediatric Diabetes Care in Sub-Saharan Africa”, and Pediatric and Adult Endocrinology Conference, “CFRD”, Winnipeg, CA 1/2010

21. Tenth Irish National CF Symposium, speaker, “Update on the new CFRD Guidelines”, Killarney, Ireland 2/2010

22. Scottish Study Group for the Care of the Young with Diabetes, speaker, “Diabetes and Cystic Fibrosis”, Pitlochry, Scotland, 3/2010.

23. Annual meeting, CF Quality Assurance Germany, keynote speaker, “The Impact of CFRD on Life and Survival in CF”, Stuttgart, Germany, 11/2011

24. Annual meeting, Diabetes UK, symposium speaker, “Diagnostic challenges in CFRD, Glasgow, Scotland, 3/2012

25. First Annual African Diabetes Congress, symposium speaker, “Pediatric diabetes in Africa”, Arusha, Tanzania, 7/2012

26. First African Diabetes Youth Leadership Program, faculty and speaker, “Diabetes Camps”, Arusha, Tanzania, 7/2012.

27. Type 1 Diabetes Post-Graduate Workshop, faculty speaker, “Diabetes in Africa, the outsider perspective”, “Hypoglycemia”, “DKA”, “Pattern recognition” “The importance of self-management education”, Arusha, Tanzania, 7/2012

28. CDiC Team Management of Pediatric Diabetes in Uganda, faculty speaker, “Pathophysiology of type 1 diabetes in Africa”, “Obesity and Type 2 Diabetes”, “Case studies---Insulin Adjustment”, Kampala, Uganda 10/2013.

29. Pediatric Grand Rounds, Mulago Hospital, “Hypoglycemia in Type 1 Diabetes”, Kampala, Uganda 10/2013

30. Guest Speaker, Institut de Recherches Cliniques de Montreal, Montreal, Canada, 1/2014 31. 14th Irish National CF Symposium, speaker, “New Insights into CFRD”, Killarney, Ireland

2/2014 32. Pediatric Grand Rounds, Cork University, “Update on CFRD”, Cork Ireland 2/2014.

Updated 2/11/2014

26

Invited North American Speaking Engagements 1. North American Cystic Fibrosis Conference, workshop speaker, "Diabetes in Cystic

Fibrosis", Washington DC, 10/89 2. Eli Lilly Fellows Conference, speaker, "Pancreatic Endocrine Function in Cystic Fibrosis",

Indianapolis, Indiana 10/89 3. North American Cystic Fibrosis Conference, workshop speaker, "Exercise in the Diabetic

Cystic Fibrosis Patient", Washington DC, 10/92 4. North American Cystic Fibrosis Conference, symposium speaker, "Diabetes in Cystic

Fibrosis", Dallas, TX 10/95 5. Northwest Regional Cystic Fibrosis Conference, keynote speaker, " CFRD", University of

Washington, Seattle, 7/97 6. North American Cystic Fibrosis Conference, Clinical Controversies debater, "Screening for

Diabetes in Cystic Fibrosis", Nashville, TN 10/97 7. Midwest Pediatric Endocrine Nurses Association, "CFRD", Mpls, MN, 2/98 8. North American Cystic Fibrosis Conference, symposium speaker, "Summary of the

Consensus Conference on Diabetes", and workshop speaker, "Management of CFRD ", Montreal, Canada 10/98

9. Western Cystic Fibrosis Consortium, plenary speaker, "CFRD", Napa, California, 3/99 10. Lawson Wilkins Pediatric Endocrine Society, plenary speaker, "Diabetes in Cystic Fibrosis",

San Francisco, CA 5/99 11. American Diabetes Association, workshop speaker, "Diabetes in CF", San Diego, CA 6/99 12. North American Cystic Fibrosis Conference, short course instructor, "The Team Approach to

Management of CFRD”, Seattle, WA 10/99 13. Indiana University Endocrinology Research Conference, “CFRD”, Indiana, IN 11/99 14. University of Iowa Pediatric Grand Rounds, “CFRD”, Iowa City, IA 3/00 15. Michigan Regional Cystic Fibrosis Conference, keynote speaker, “CFRD”, Detroit, MI 4/00 16. Massachusetts General Hospital Pediatric Grand Rounds, “CFRD”, and Endocrine Research

Conference, “Ongoing Metabolic Research in CF”, Boston, MA 5/00 17. The Endocrine Society, “Meet the Professor” session, “Endocrine Complications of Cystic

Fibrosis”. Toronto, CA 6/00 18. New Jersey Regional Cystic Fibrosis Conference, keynote speaker, “CFRD”, East

Brunswick, New Jersey, 7/00 19. Columbia University Pediatric Grand Rounds, “CFRD”, New York, 7/00. 20. North American Cystic Fibrosis Conference, workshop speaker, “CFRD", and short course

instructor, "The Team Approach to Management of CFRD", Baltimore, MA 11/00 21. North American Cystic Fibrosis Conference, workshop speaker, "Lipid Abnormalities in

Cystic Fibrosis", Baltimore, MA 11/00 22. Denver Children’s Hospital Pediatric Grand Rounds, “CFRD”, Denver, CO, 3/01 23. Orange County Regional CF Conf., keynote speaker, “CFRD”, Orange County CA, 4/01 24. The Endocrine Society, “Meet the Professor” session, “Endocrine Complications of CF”, and

symposium speaker, “Growth Hormone Therapy in Cystic Fibrosis”. Denver, Co 6/01 25. Genentech Regional Manager's Meeting, “GH Therapy in CF” Mpls, MN, 2/02. 26. Milwaukee Children's Hospital Pediatric Grand Rounds, “CFRD”, Milwaukee, WI, 3/02 27. Mountain West Cystic Fibrosis Consortium, keynote speaker, “CFRD”, Phoenix, AZ, 6/02. 28. Vanderbilt Pediatric Grand Rounds, “Cystic Fibrosis Related Diabetes”, Memphis, TN, 9/02. 29. Washington University Pediatric Grand Rounds, “CFRD”, St. Louis, Missouri, 3/03. 30. Northern New England Cystic Fibrosis Consortium, keynote speaker, “Cystic Fibrosis

Related Diabetes”, Durham, NH, 4/03

Updated 2/11/2014

27

31. American Diabetes Association, symposium speaker, “Cystic Fibrosis Related Diabetes: Diagnosis and Management”, New Orleans, 6/03

32. Baylor Grand Rounds, “CFRD”, Dallas, TX 11/2003 33. Boston Children’s Hospital Endocrine Seminar, “CFRD”, Boston, MA 11/2003 34. Joslin Diabetes Center Grand Rounds, “CFRD”, Boston, MA 11/2003 35. Mass General Hospital for Children Endocrine Seminar, “CFRD”, Boston, MA 11/2003 36. Indiana University Grand Rounds, “CFRD”, Indianapolis, IN 1/2004 37. University of Michigan Hospital Medical Grand Rounds, “CFRD”, Ann Arbor, MI 2/2004 38. University of Wisconsin Pediatric Grand Rounds, “CFRD”, and Endocrinology Grand

Rounds, “CFRD”, Madison, WI 3/2004 39. Rhode Island Hospital 13th Annual Contemporary Topics in Nutrition Symposium, “CFRD in

Adults and Children”, Providence, RI 3/2004 40. Brown Medical School Endocrinology Grand Rounds, “CFRD”, Providence, RI 3/2004 41. Midwest Mountain Consortium annual meeting, short course leader, “CFRD, a practical

course on diagnosis and treatment”, Boulder, Colorado 6/2004 42. SIU School of Medicine, Medicine Journal Club, “CFRD”, Springfield, IL 9/2004 43. University of Illinois, St. Francis Hospital, Peds Grand Rounds, “CFRD”, Peoria, IL 9/04 44. North American Cystic Fibrosis Conference, symposium speaker, "Cystic Fibrosis Related

Diabetes, Pathophysiology and Prognosis", St. Louis, MO, 10/04 45. Mount Sinai School of Medicine Pediatric Grand Rounds, “CFRD”, New York 11/04 46. Lawson Wilkins Pediatric Endocrine Society Fellow’s Course, speaker, “Academic

Mentoring, What to Look For and What to Avoid”, Greenwich, Connecticut, 11/04 47. Children’s Hospital of Philadelphia, Endocrine Symposium, and CF Team Symposium,

“CFRD”, Philadelphia, PA 4/05 48. South Central CF Consortium annual meeting, speaker, “CFRD” and “Osteoporosis in CF”,

Houston, TX 4/05 49. LWPES Review Course, speaker, “CFRD”, San Diego, CA 5/05 50. Children’s Hospital, Kansas City, Missouri, speaker, “CFRD”, 9/05 51. Pediatric Grand Rounds, Via Christi Hospital, and CF Family Education Day, Wichita,

Kansas; “CFRD”, and “Osteoporosis in CF”, 10/05 52. North American Cystic Fibrosis Conference, symposium speaker, "Dietary mediators of

inflammation", and short course speaker “Diagnosis and Management of CFRD”, Baltimore, MA 10/05

53. Hulda Wohltmann Lecture, University of South Carolina, Charleston, “CFRD: A Path From Clinical Research to Clinical Practice”, 3/06

54. North American Cystic Fibrosis Conference, nutrition seminar speaker, "Microvascular complications of CFRD, and short course speaker “Diagnosis and Management of CFRD”, Denver, CO 11/06

55. Barbara Davis Center, speaker, “CFRD”, Denver, CO 11/06 56. Johns Hopkins Medical Center Endocrine Grand Rounds, “CFRD”, Baltimore, MD 4/07 57. CF Family Education Day, Children’s Memorial Hospital, “CFRD”, Chicago, IL 4/07 58. Rainbow Babies and Children’s Hospital Pulmonary and Endocrine Seminar, “CFRD”,

Cleveland OH 5/07 59. NACF Conference, nutrition seminar speaker, "Hypoglycemia in CF”, Anaheim, CA 10/07 60. University of Massachusetts Pediatric Grand Rounds, “CFRD”, Worcester, MA 2/08. 61. Columbia University Adult CF Care Symposium speaker, “CFRD”, New York, NY, 3/08 62. Emory Pediatric Grand Rounds, “CFRD”, Atlanta, Georgia, 4/08

Updated 2/11/2014

28

63. American Thoracic Society annual meeting, invited speaker, “Managing and Preventing CFRD”, Toronto, CA, 5/08

64. American Diabetes Association Annual Meeting, Pediatric Diabetes Special Interest Section: Pediatric Diabetes in the Developing World, speaker, “Status of Pediatric Diabetes Care in Sub-Saharan Africa”, San Francisco, CA 6/08

65. North American Cystic Fibrosis Conference, symposium speaker, "Update on CFRD”; brown bag session leader “Tricks to Intensive Insulin Management in CF”, and special session presenter “CFRD Management for the Endocrinologist”; Orlando, Florida 10/08

66. Cystic Fibrosis Family Education Day, speaker, “CFRD”, Sioux Falls, SD, 11/08 67. University of Chicago Endocrine Research Symposium, speaker, "Update on CFRD”,

Chicago, IL 11/08 68. Pediatric Academic Societies annual meeting, symposium speaker, “Carbohydrate

Metabolism in CF”, Baltimore, MD, 5/09 69. American Diabetes Association annual meeting, symposium speaker, “Cystic Fibrosis

Related Diabetes”, New Orleans, LA, 6/09 70. North American Cystic Fibrosis Conference, symposium speaker, "Updates of CFRD

Consensus Guidelines”, Minneapolis, MN 10/2009 71. University of Pennsylvania Endocrine Research Conference invited speaker “CFRD

Pathophysiology and Prognosis” and University-Wide Endocrine Conference speaker “CFRD Diagnosis and Treatment”, Pittsburg, 11/2009.

72. Annual CF Learning Center Continuum of Care Conference, speaker, CF Complications: CFRD, Bones and other Metabolic Diseases”, Jersey City, NJ, 4/2010

73. Endocrinology Research Lecture, speaker, Nebraska Medical Center, Omaha, NE 5/10 74. 10th Annual MidAtlantic Regional CF Consortium , plenary speaker, “New Issues in Adult

and Pediatric CFRD” and Bone Disease in CF”, Philadelphia, 5/10 75. Visiting Professor, Update on CFRD, Emory, Atlanta, Georgia, 7/10 76. Stephanie Lynn Kossoff Memorial Lecture, “CFRD”, Morgan Stanley Children’s Hospital,

New York 9/10 77. Naomi Berrie Diabetes Center Lecture, “Update of CFRD”, Columbia University, New

York, 9/10 78. University of Illinois, Peoria Pediatric and Medicine Grand Rounds, “Update on CFRD”,

Peoria, Illinois, 1/2011. 79. NIH CFRD Special Workshop, Keynote address: “CFRD: Overview of our current

understanding and where do we go from here?” Bethesda, MD, 5/11 80. 10th Annual Regional CF Consortium, speaker: “CFRD issues in adult and pediatric patients”

and “Bone Health in CF”. Philadelphia, 5/11 81. West Virginia University, Grand Rounds: “Update on CFRD”. Morgantown, WV 7/11 82. Pacific Northwest Research Institute, seminar speaker, “New Research Directions in CFRD”,

Seattle, WA, 8/11 83. University of Washington CF Research External Advisory Committee, keynote speaker,

“New Research Directions in CFRD”, Seattle, WA, 8/11 84. Great Plains Pediatric Symposium, Children’s Mercy Hospital, speaker, “Diagnosis and

management of CFRD. Kansas City, 10/11 85. 5th Annual Diabetes Symposium of Wisconsin, symposium speaker, Update on CFRD.

Milwaukee, WI, 5/2012 86. American Diabetes Association, symposium speaker, IL-1 Blockade and the Treatment of

Diabetes, Philadelphia, PA, 6/12

Updated 2/11/2014

29

87. Pediatric Grand Rounds, Arnold Palmer Hospital for Children, speaker, Management of CF Related Diabetes, Orlando, FL, 12/12

88. American Pediatric Association, speaker, APA Global Health Special Interest Group, “Successful approaches and partnerships to address non-communicable disease in developing countries”. Vancouver, Canada, 5/2014

89. American Thoracic Society Annual meeting, symposium speaker, “Impact of CF-related diabetes on lung function and survival in CF”, San Diego, California, 5/2014

90. North Dakota State University, symposium speaker, “Approaches to curing of type 1 diabetes”, Fargo, ND, 5/2014

91. Cystic Fibrosis Research Institute 27th Annual National CF Family Education Conference, speaker, San Francisco 8/2014

Local/Regional Speaking Engagements 1. Clinical Research Center Grand Rounds, "Diabetes and Cystic Fibrosis", 3/88 2. Clinical Research Center Grand Rounds, "Endocrine Function in Cystic Fibrosis ", 3/89 3. UMHC Pediatric Grand Rounds, "Pancreatic Endocrine Function in Cystic Fibrosis ", 5/89 4. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/89 5. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/90 6. Citywide Diabetes, Endocrinology and Metabolism seminar, "Pancreatic Endocrine Function

in Cystic Fibrosis ", 4/91 7. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/91 8. Clinical Research Center Grand Rounds, "The Potential Use of GH Therapy in CF", 2/92 9. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/92 10. Medicine Grand Rounds, UMCH, "Insulin Sensitivity in Cystic Fibrosis", 1992 11. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/93 12. Topics and Advances in Pediatrics, UMHC, workshop speaker, "Common Endocrine

Problems in Childhood", 6/94 13. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/94 14. Grand Rounds, St. Paul Ramsey Hospital. "Short stature: diagnosis, monitoring and

treatment", 1995 15. Minnesota CF Parent Consumer Conference, "Endocrine Issues in Cystic Fibrosis ", 11/95 16. UMHC Pediatric Grand Rounds, "Diabetes and Glucose Intolerance in CF", 4/96 17. Topics and Advances in Pediatrics, UMHC, "Short stature: diagnosis, monitoring and

treatment", 6/96 18. Topics and Advances in Pediatrics, UMHC, workshop speaker, "Normal and Abnormal

Puberty", 6/96 19. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/96 20. Citywide Diabetes, Endocrinology and Metabolism seminar, 3/97 "Diabetes in CF". 21. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/97 22. American Diabetes Association, Great Lakes Regional Chapter, 4/98 "'Activity and Exercise

in Persons with Diabetes. Duluth, MN 23. American Diabetes Association, Minnesota Affiliate, 4/98 "Exercise in Children with

Diabetes. St. Paul, MN. 24. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/98 25. Citywide Diabetes, Endocrinology and Metabolism seminar, 5/99 "Management of Pediatric

Diabetes". 26. Practical Pediatrics for the Primary Care Physician, Children’s Hospitals and Clinics, Session

speaker, “Delayed Puberty: Is It Pathologic?” 9/99

Updated 2/11/2014

30

27. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/99 28. FUMC Comprehensive Diabetes Update, "Diabetes in Cystic Fibrosis " 11/99. 29. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/00 30. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/01 31. FUMC Comprehensive Diabetes Update, "Diabetes in Cystic Fibrosis " 11/01. 32. University of Minnesota Pediatric Grand Rounds, "Cystic Fibrosis Related Diabetes", 4/02 33. University of Minnesota Lillehei lecture: "Cystic Fibrosis Related Diabetes", 5/03 34. Minnesota CF Parent Consumer Conference, "Diabetes in Cystic Fibrosis ", 11/03 35. Topics and Advances in Pediatrics, University of Minnesota, speaker and panel participant,

"Future Management of Diabetes Mellitus", 6/05 36. Minnesota CF Parent Consumer Conference, "Update on Endocrine Issues in CF", 11/03 37. Citywide Diabetes, Endocrinology and Metabolism seminar, "Update on Research in Cystic

Fibrosis Related Diabetes", 12/05 38. Minnesota CF Parent Consumer Conference, "Diabetes and Osteoporosis: Common

Endocrine Problems in Cystic Fibrosis", 11/05 39. Pediatric Grand Rounds, “Cystic Fibrosis Related Diabetes: A Story of Clinical Research at

the University of Minnesota Changing International Standards”. 2/06 40. Citywide Diabetes, Endocrinology and Metabolism seminar, "Update on TrialNet", 1/07 41. Duluth Clinic Annual CME course, “Can Type 1 Diabetes Be Prevented”, Duluth, MN 1/08 42. Global Health Awareness Week Lecture: “Diabetes: Challenges to Managing Chronic Illness

in a Developing Nation”, 2/08 43. Pediatric Grand Rounds, “Pediatric Diabetes as a Model of Chronic Illness in Africa---Can

We Make a Difference?”, 9/08 44. University of Minnesota Duluth Academy of Science and Engineering lecture, “Type 1

Diabetes Prevention”, Duluth, MN 10/08 45. American Association of Clinical Endocrinologists Minnesota-Midwest Chapter, speaker,

“New Experimental Therapies for Type 1 Diabetes”, St. Paul, MN 11/08 46. Citywide Diabetes, Endocrinology and Metabolism seminar, “New Experimental Therapies

for Type 1 Diabetes”, Minneapolis, MN 12/08 47. Stem Cell Institute seminar, “Cellular Therapies for Type 1 Diabetes, Minneapolis, MN 6/09 48. Topics and Advances in Pediatrics, University of Minnesota, speaker and session leader,

"New Approaches to Cure Type 1 Diabetes", Mpls, MN 6/09 49. Minnesota CF Parent Consumer Conference, plenary speaker, "CFRD, update on new

recommendations", 11/09 50. Fairmont Rotary Club, "New Approaches to Cure Type 1 Diabetes", Fairmont, MN 9/09 51. Lion’s Club Convention, speaker, "New Approaches to Cure Type 1 Diabetes"; Alexandria

Community Education, speaker, “Adult and Pediatric Diabetes” Alexandria, MN, 1/10 52. UM Mini Medical School, “Diabetes: a World-Wide Epidemic”, Mpls, MN 4/10 53. Topics and Advances in Pediatrics, University of Minnesota, speaker, "Type 2 diabetes in

youth--- the tip of the iceberg", Mpls, MN 6/10 54. City-Wide Endocrine Conference, “Update on Diabetes Prevention Trials”, Mpls, MN 12/10 55. Minnesota CF Parent Consumer Conference, "Update on CFRD Research", 11/12 56. City-Wide Endocrine Conference, “Update on Diabetes Prevention Trials”, Mpls, MN 1/13 57. Minnesota CF Parent Consumer Conference, "Update on CFRD ", 11/13

TEACHING

Updated 2/11/2014

31

Educational Activities Lectures to medical and graduate students and residents - G-protein clinical correlation lecture, first year medical students 1994-96 - Sexual development symposium lecturer, first year medical students 1998-9 - Puberty lecture, second year medical students 1995-2007 - Sexual differentiation and ambiguous genitalia lecture, second year medical students

1995-2007 - Small group endocrine tutorials, second year medical students 1995-present - Pediatric resident core conference lectures (2 per year---DKA, pediatric thyroid

problems, precocious puberty, delayed puberty, ambiguous genitalia) 1995-2012 - Nutrition Grad Students, “Energy Balance” course-euglycemic clamp technique 2000-3 - Global Health Course lecturer, “Diabetes in Africa”, 2007-present - Visiting lecturer, Mulago Hospital resident conferences: “Type 1 diabetes”, “Type 2

diabetes and obesity", “DKA”, “Hypo-and hyperthyroidism”, “Ambiguous genitalia”, “Disorders of calcium and bone”, “Normal growth and short stature”, “Normal and abnormal puberty”. 2007, 2008

- Master’s in Clinical Research program epidemiology course: “Developing an Academic Career”, 2011

- BIRCWH K12 seminar, “Writing an Innovation Section”, 2011 - PubH6303 Clinical Research Project Seminar, “Creating a clinical research path”, 2010,

2011, 2012 - Fellowship Core Curriculum, “Mentor—what to look for and what to avoid”, given every

other year 2009-present Undergraduates

-UM Honors Course: Global Health Issues for Future Health Professionals, lecture- “Type 1 Diabetes in Africa”, 2008

- Macalester College Global Health Scholars Program, lecture-“Type 1 Diabetes in Africa”, 2012

Community Education

-Annual RPAP faculty visitor 1991-2001 Course Directorship

-Endocrinology second year medical student course committee, Director of pediatric section 1995-2007

Mentoring

High School − Kiltie McGowan, 2002, national high school science project (currently a biomedical

engineer with Medtronic, Diabetes Division) Undergraduates

− Noelle Otten, 2006 (currently a UM medical student) − Connor Lewis 2013 (currently a UM Morris biostats student)

Medical Students − Michael Armstrong 1999-2001, MD/PhD co-advisor (currently a hematologist ,Duke)

Graduate Students − Fiona Anderson PhD, 2001-3, post-doc (currently an Assistant Professor at UM)

Updated 2/11/2014

32

Residents − Andrew Riggs MD, 2000, Medicine-Pediatrics resident (currently a pediatric

endocrinology at Peyton Manning Children’s Hospital, Indianapolis) − Veronique Figueroa MD PhD, 2000, visiting pediatrics resident from Argentina

(currently a practicing pediatric endocrinologist in Buenos Aires). Fellows

− Carlos Milla MD, 1992-95 (currently an Associate Professor and Director of the Cystic Fibrosis Center, Stanford)

− Amy Criego MD, 2002-5 (currently a practicing pediatric endocrinologist) − Irene Hong-McAtee MD, 2003-6 (currently an Associate Professor at Vanderbilt) − Betsy Schwartz MD, 2004-7 (currently a practicing pediatric endocrinologist) − Lynda Polgreen MD, 2005-8 (currently an Assistant Professor, UM) − Melena Bellin MD, 2006-9 (currently an Assistant Professor, UM) − Brigitta Frohnert MD, 2007-10 − Katie Larson-Ode, 2008-2011 (currently an Assistant Professor, U Iowa) − Muna Sunni, 2010-2013 (currently an Assistant Professor, UM) − Eva Oberdorfer 2011-2014 − Tanya Halvorson 2012-2015 − Greg Forlenza 2013-2015

Junior Faculty − Julia Steinberger MD, 2001-2, Master’s Degree in Clinical Research co-mentor

(currently a Professor, UM Pediatric Cardiology) − JoAnne Billings MD, 2002-07, K23 co-mentor (currently an Assistant

Professor, UM) − L’Aurelle Johnson PhD , 2007-10, CAPS K12 co-mentor − Lynda Polgreen MD, 2008-13, CAPS K12/K23 co-mentor (currently an

Assistant Professor, UM) − Melena Bellin MD, 2010-2015, K23 mentor (currently an Assistant Professor,

UM) − Brandon Nathan, MD 2007-present, academic mentor (currently an Assistant

Professor, UM) − Chris Boys, PhD, 2007-present, academic mentor (currently an Assistant

Professor, UM) − Ioanna Apostolidou, 2010-present, Master’s research advisor (currently an

Assistant Professor, UM)

Masters Thesis, PhD Dissertation or Scholarship Oversight Committees Hyon Jeong Kim, MD/PhD, 2003 David Kwan, Masters Degree in Public Health, 2003 Erin Donaher (Chair) 2004-7 Erica Holt, Master’s Degree in Public Health, 2006 Sheri Crow, Master’s Degree in Clinical Research, 2007 Mohamed Eid, Master’s Degree in Clinical Research, 2007 Xiaobo Liu, Master’s Degree in Biostatistics, 2008 Chad Best, MD, Master’s Degree in Clinical Research, 2009 Melena Bellin, MD, Master’s Degree in Clinical Research, 2009 Lynda Polgreen, MD, Master’s Degree in Clinical Research, 2009 Greg Sindberg, PhD, Comparative and Molecular Biosciences, College of Veterinary Med, 2010

Updated 2/11/2014

33

Vickie Holker, PhD, University of N. Dakota, 2011 Ioanna Apostolidou, MD, Master’s Degree in Clinical Research 2012 Jill Dreyfus, PhD in Epidemiology, 2013 Educational Consulting - Consultant, Health Learning Systems (diabetes education materials for MDs) 1999 - Advisory Board, Protocol Driven Healthcare, Inc, www.mycysticfibrosis.com web site 2001-

2009 (CF education materials for patients) - Consultant, Clinical Issues in the Management of Cystic Fibrosis: A Pulmonology Forum.

Colorado Springs, CO, 8/04 (CF education materials for physicians) - Consultant, Boomer Foundation, 4/08, Adult Issues in CF (development of strategies for

adult endocrinologist-pulmonologist partnerships in CFRD care) - Rush University Medical Centers Speaker’s Bureau, faculty, “Clinical Viewpoints: A CME

Lecture Series for Cystic Fibrosis”, 2013

CLINICAL RESPONSIBILITIES

- Two days per week Pediatric Diabetes Clinic - Two-three half days per month Cystic Fibrosis Diabetes Clinic - Six weeks per year in-patient clinical service

CLINICAL PROGRAM RECOGNITION 2009 US News and World Reports Top 30 Pediatric Diabetes Program 2011 US News and World Reports Top 50 Pediatric Diabetes Program 2011 Medtronic “Excellence in Innovation” award (national award to a single pediatric diabetes

program) 2012 US News and World Reports Top 50 Pediatric Diabetes Program

- Consulting: Pfizer (2011, 2013), CordUse (2013), Vertex (2014) - Honoraria for speaking engagements: Aventis (2004, 2005), Chiron (2005) - Industry Advisory Boards: Genzyme (2006), Tercica (2006), Aventis (2007), Bayer (2008),

Novo Nordisk (2009), Abbott (2011), Medtronic (2013) - Industry Data Safety Monitoring Board: Novo Nordisk (2012-2015) - Research Grant Support Investigator-Initiated: Aventis (2002-5) - Research Grant Support Pharma-Initiated: Prochymal (2008-11), Tolerx (2010-2013), Pfizer

(2011-2014), Novartis (2012-2018) - Research Grant Supplies Only: Novo Nordisk (2001-7), Lifescan (2001-7), Merck (2010-11)

CLINICAL SERVICE

DISCLOSURES (last 10 years)

Date post:	01-Jun-2020
Category:	Documents
Upload:	others
View:	1 times
Download:	0 times

CURRICULUM VITAE MORAN 2-11-2014 · Clinical Nutrition (2011-12) Clinical Orthopaedics & Related...

Documents